GeneDx Holdings (WGS) Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Accumulated Expenses for 7 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 75.81% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 75.81% YoY), while the FY2025 annual figure was $44.7 million, up 258.91% from the prior year.
• Accumulated Expenses eased to $24.7 million in Q1 2026 per WGS's latest filing, from $44.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $44.7 million in Q4 2025 and bottomed at $7.3 million in Q2 2024.
• Historically, Accumulated Expenses has averaged $20.0 million across 5 years, with a median of $18.5 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses tumbled 59.04% — and 2025, when it jumped 285.52%.
• GeneDx Holdings' Accumulated Expenses stood at $20.3 million in 2022, then plunged by 40.05% to $12.2 million in 2023, then advanced by 2.17% to $12.4 million in 2024, then surged by 258.91% to $44.7 million in 2025, then slumped by 44.79% to $24.7 million in 2026.
• Business Quant data shows WGS's Accumulated Expenses at $24.7 million in Q1 2026, $44.7 million in Q4 2025, and $26.4 million in Q3 2025.